Novo Nordisk's CagriSema helps patients lose over 20% body weight in late-stage obesity trial.

Novo Nordisk partners with Septerna in a $2.2 billion deal to develop oral treatments for obesity, type 2 diabetes, and other metabolic diseases.

Novo Nordisk reassures investors with strong growth forecasts, rising GLP-1 drug demand, and promising new treatments despite market challenges.

Novo Nordisk launches Wegovy in China, offering an effective weight-loss solution for about 180 million obese Chinese population, though not covered by insurance.

A new study reveals that semaglutide, a key ingredient in Ozempic and Wegovy, reduces the risk of dying from Covid-19 by 33%, [otentially boosting its market value.

Shares of pharmaceutical companies Novo Nordisk and Eli Lilly slid after Roche announced results from a promising early-stage trial for its proposed obesity drug.

A new study published in JAMA Ophthalmology suggests that taking Ozempic or Wegovy may increase the risk of developing a rare form of blindness.

President Joe Biden and Senator Bernie Sanders have urged Novo Nordisk and Eli Lilly to lower the prices of their popular weight loss drugs.

Novo Nordisk announced a $4.1 billion investment to build a new manufacturing plant in Clayton, North Carolina, to increase production capacity for its popular drugs Wegovy, Ozempic, and other injectable therapies.

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate following Sen. Bernie Sanders' threat to subpoena the company over the pricing of diabetes drug Ozempic and obesity drug Wegovy.